Daniel B. Soland
Daniel B. Soland's purchase track record
Daniel B. Soland has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/1/2023 | DBVT | $24K | -37.3% | -46.0% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
DBVT ADRs See Minor Gains as European ADRs Rise. The group of European stocks traded as ADRs in the U.S. edged up on Tuesday and opened higher on Monday. DBVT, an ADR of DBV Technologies, was part of that group and saw a modest lift in its price. The move reflects broader market sentiment for European ADRs rather than a company‑specific event.
Transaction History
| ACAD | ▲ Buy | Option Exercise | 9,387 | — | 5/29/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,652 | — | 5/29/2024 | View on chart |
| DBVT | ▲ Buy | Open Market | 15,000 | $24K | 8/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,552 | — | 6/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,391 | — | 6/7/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,059 | — | 6/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.